Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004)in the Treatment of Ankylosing Spondylitis (AS).

Trial Profile

Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004)in the Treatment of Ankylosing Spondylitis (AS).

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2015

At a glance

  • Drugs Apremilast (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Acronyms START
  • Most Recent Events

    • 14 Sep 2012 Results published in Annals of the Rheumatic Diseases.
    • 14 Sep 2012 Primary endpoint 'Bath-Ankylosing-Spondylitis-Disease-Activity-Index' has not been met, according to results published ARD.
    • 07 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top